Active Pharmaceutical Ingredient (API) Manufacturing is Projected to Record a Major Growth in China Pharmaceutical Contract Manufacturing Market

The china pharmaceutical contract manufacturing market is anticipated to grow at a considerable CAGR of around 12.1% during the forecast period (2021-2027). The increasing demand for API manufacturing has witnessed constant growth over the given forecast period. Also, it is projected to continue increasing with further patent expirations estimated in the future, and a resulting rise in the generic production capacities. Additionally, the major companies in the market are increasingly focusing on the advancement of biological APIs, which is boosting the market growth. Additionally, the generic prescription drug has more demand for API manufacturing, as compared to OTC drugs. Moreover, the growing government development in the healthcare sector, increase in the incidence of cancer and age-related diseases, and advancement in biologics are some factors that drive the growth of the market. 

Browse the full report description of "China Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Manufacturing Process Type (Sterile Manufacturing, and Non-Sterile Manufacturing), By Product Type (Over-The-Counter (OTC) Drugs, Active Pharmaceutical Ingredients (API), Finished Dosage Formulation, and Others), By Route of Administration (Oral Administration, Inhaled Administration, Parenteral Administration, and Others), By Service (R&D, Manufacturing, and Non-Clinical Service) Forecast, 2021-2027" at  https://www.omrglobal.com/industry-reports/china-pharmaceutical-contract-manufacturing-market

For Instance, in November 2018, Catalent Pharma Solutions, one of the leading global providers of innovative delivery technologies, and development solutions for drugs, biologics, and consumer health products, announced its plans to invest $2.5 million in a new, second clinical supply facility in Shanghai, China.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Surgery

o By Product

o ByEnd-user

• Competitive Landscape - Bayer AG, GlaxoSmithKline PLC, Merck & Co., Inc., Pfizer Inc., WuXi AppTec, Evonik Industries AG, Boehringer Ingelheim International GmbH, Zhejiang Jingxin Pharmaceutical Co., Ltd.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

China pharmaceutical contract manufacturing

By Process Type

• Sterile Manufacturing
• Non-Sterile Manufacturing

By Product Type

• Over-The-Counter (Otc) Drugs
• Active Pharmaceutical Ingredients (API)
• Finished Dosage Formulation
• Others (Nutritional Products And Packaging)

By Route of Administration

• Oral Administration
• Inhaled Administration
• Parenteral Administration
• Others (Rectal And Vaginal)

By Service

• R&D, Manufacturing
• Non-Clinical Service Such As Supply Chain Management

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/china-pharmaceutical-contract-manufacturing-market